与酒精相关的肝病中的血小板:与中性粒细胞的相互作用
Juan Wang1, Xianda Wang1, Haodong Peng2
1Department of Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China; Innovation and Entrepreneurship Laboratory for College Students, Anhui Medical University, Hefei, Anhui, China; Inflammation and Immune-Mediated Diseases Laboratory of Anhui Province, Anhui Medical University, Hefei, Anhui, China.
Cellular and molecular gastroenterology and hepatology
|March 10, 2024
概括
血小板在与酒精相关的肝病 (ALD) 中发挥着关键作用,通过促进中性粒细胞的迁移和激活,从而加剧肝损伤. 针对血小板-中性粒细胞相互作用,为ALD提供了一个有前途的治疗策略.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 免疫学 免疫学 免疫学
- 血液学 血液学 血液学
背景情况:
- 酒精相关性肝病 (ALD) 是全球肝脏死亡的主要原因.
- 中性粒细胞的透是酒精性脂肪肝炎的关键特征,但血小板在这个过程中的作用还未得到充分研究.
- 血小板越来越多地被认为参与肝脏损伤和修复.
研究的目的:
- 审查血小板和中性粒细胞在肝脏病理生理学中的复杂作用,特别是ALD.
- 在ALD的背景下,巩固最近关于血小板-中性粒细胞相互作用的发现.
- 突出针对这些相互作用的潜在治疗策略,用于ALD治疗.
主要方法:
- 对最近关于血小板,中性粒细胞和ALD的研究进行文献综述.
- 关于肝损伤中血小板与中性粒细胞相互作用的发现的巩固.
- 在血小板-中性粒细胞通路内确定治疗点.
主要成果:
- 血小板对于中性粒细胞迁移到肝损伤部位至关重要.
- 血小板激活增强中性粒细胞激活,导致肝损伤增加.
- 血小板-中性粒细胞复合体和中性粒细胞外细胞陷加剧了ALD的发病过程.
- 降低血小板水平减少了中性粒细胞的招募.
结论:
- 血小板和中性粒细胞在ALD的发病过程中扮演着复杂的相互关联的角色.
- 针对血小板-中性粒细胞相互作用,为ALD提供了一个新的治疗途径.
- 对操纵这些相互作用的进一步研究可能会导致创新的ALD治疗方法.
更多相关视频
相关概念视频
Formation of the Platelet Plug
6.2K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
6.2K
Inflammation
53.4K
Overview
53.4K
Introduction to Hemostasis
7.7K
Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
7.7K
Structure and Function of Platelets
1.2K
The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
1.2K
Anticoagulant Drugs: Low-Molecular-Weight Heparins
696
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
696
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
523
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
523


